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A B S T R A C T
Background: Despite good treatment, there are residual risks in acute myocardial infarction (AMI)
patients, and low level of high-density lipoprotein-cholesterol (HDL) has drawn attention as a possible
cause. However, the impact of low HDL on ST-segment-elevation myocardial infarction (STEMI)
compared with non-ST-segment-elevation myocardial infarction (NSTEMI) is not clear. Our aim was to
evaluate the impact of low HDL on clinical outcomes in patients with STEMI or NSTEMI.
Methods: We included 9270 AMI patients undergoing successful percutaneous coronary intervention.
They were grouped into STEMI and NSTEMI, and subdivided into two groups according to HDL level
sampled in overnight fasting state. Primary end point was in-hospital death. Secondary end point
was a composite of major adverse cardiac events (MACE) in hospital survivors during one-year
follow-up.
Results: In the STEMI population, low HDL group showed signiﬁcantly higher in-hospital death rate
[4.6% vs. 1.4%, hazard ratio (HR): 2.380, 95% conﬁdence interval (CI): 1.143–4.956, p = 0.020] than
normalHDL group. InNSTEMI population, therewas no signiﬁcant difference between two groups (1.8%
vs. 0.9%, HR: 1.231, 95% CI: 0.649–2.335, p = 0.525), but in subgroup analysis, very low HDL subgroup
showed higher in-hospitalmortality rate comparedwith normal HDL group (4.0% vs. 0.9%, respectively,
p = 0.009). In 12-month MACE rates, there was no signiﬁcant difference between two groups in both
populations.
* Corresponding author at: Principal Investigator of Korea Acute Myocardial Infarction Registry, Director of Heart Research Center Designated by Korea Ministry of Health
and Welfare, Chonnam National University Hospital, 671 Jaebong-ro, Dong-gu, Gwangju 501-757, Republic of Korea. Tel.: +82 62 220 6243; fax: +82 62 228 7174.
E-mail addresses: myungho@chollian.net, myungho@chol.com, mhjeong@chonnam.ac.kr (M.H. Jeong).
1 See Acknowledgments.
http://dx.doi.org/10.1016/j.jjcc.2014.04.002
0914-5087/ 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
Conclusions: Low HDL was associated with signiﬁcantly higher risk of in-hospital mortality in STEMI
patients, but not in NSTEMI patients. Thus, more aggressive treatment should be considered in STEMI
patients with low HDL.
 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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Traditionally, low-density lipoprotein-cholesterol (LDL) has
been regarded as a major risk factor in patients with acute
myocardial infarction (AMI), and lowering LDL level has been a
main target inmedical treatment. However, there are residual risks
in AMI patients treated with LDL-lowering therapy, and recently,
low level of high-density lipoprotein-cholesterol (HDL) has drawn
attention as a potential cause [1–3].
However, there have been controversies about the impact of
HDL on clinical outcome in non-ST-segment-elevation myocardial
infarction (NSTEMI) patients [4–6], while there is lack of data in ST-
segment-elevation myocardial infarction (STEMI) patients [7].
Considering different clinical features of STEMI and NSTEMI [8], it
might be important to compare the impact of HDL on clinical
outcome in both populations. Moreover, there have been few
studies analyzing this issue in hospital survivors.
Therefore, the purpose of this study was to investigate the
impact of HDL on the clinical outcome in STEMI patients and in
NSTEMI patients, simultaneously, using the database of the Korea
Acute Myocardial Infarction Registry (KAMIR).
Methods
Study design and patients
The KAMIR is the largest multicenter data collection registry in
Korea, designed to evaluate the outcomes of AMI patients,
including 51 hospitals and to store data for them [9]. Data were[(Fig._1)TD$FIG]
Fig. 1. Patient ﬂow chart. (I) In-hospital mortality and (II) 12-month outcomes. KAMIR, K
high-density lipoprotein; STEMI, ST-segment-elevation myocardial infarction; NSTEMI,collected at each hospital by well-trained study nurses based on a
standardized protocol. Our study was conducted according to the
Declaration of Helsinki. The study protocol was approved by
institutional review boards of all centers, and the approval number
was 05-49 of Chonnam National University Hospital. Written
informed consent was obtained from all patients.
The patient ﬂow chart is shown in Fig. 1. Of a total of 14,885
patients whowere enrolled in the KAMIR betweenNovember 2005
and January 2008, we selected 9270 AMI patients who underwent
successful percutaneous coronary intervention and in whom HDL
level could be identiﬁed. For the evaluation of in-hospital
mortality, patients were grouped into STEMI (n = 6110) and
NSTEMI (n = 3160), and subdivided into two groups according to
HDL level; low HDL (n = 2667), normal HDL (n = 3443) in STEMI;
low HDL (n = 1514), normal HDL (n = 1646) in NSTEMI.
For the evaluation of 12-month outcomes, we selected 9056
hospital survivors: low HDL (n = 2543), normal HDL (n = 3395) in
STEMI; low HDL (n = 1487), normal HDL (n = 1631) in NSTEMI.
For subgroup analysis, patients were categorized into three
subgroups according to HDL level: very lowHDL (HDL< 30mg/dL),
lowHDL(30  HDL< 40 inmale,<50 in female,mg/dL), andnormal
HDL (HDL 40 in male, 50 in female, mg/dL).
Deﬁnitions
The diagnosis of AMI was based on clinical signs or symptoms,
including increases of serum cardiac biomarkers (creatine kinase-
MB, troponin I, or troponin T) and speciﬁc changes on 12-lead
electrocardiographic ﬁndings. STEMI was deﬁned as ST-segmentorea Acute Myocardial Infarction Registry; AMI, acute myocardial infarction; HDL,
non-ST-segment-elevation myocardial infarction.
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NSTEMIwas deﬁned as all other cases in AMI. LowHDL-cholesterol
was deﬁned as the level lower than 40 mg/dL in men or 50 mg/dL
in women.
The primary end point was in-hospital death including all-
cause death. The secondary end point was a composite of major
adverse cardiac events (MACE) including cardiac death, myocar-
dial infarction (MI), and target vessel revascularization (TVR) in
hospital survivors during one-year follow-up. Cardiac death was
deﬁned as death due to pump failure, arrhythmia, mechanical
complication such as ventricular septal defect or free wall
rupture, or other cardiac cause. TVR was deﬁned as percutaneous
coronary intervention in coronary artery including target
lesion [10].
Blood samples were collected at admission, except for lipid
proﬁles, which were measured from blood sampled in overnight
fasting state. Optimal medical therapies were used in patients
during hospitalization and after discharge. Coronary artery
angiography and stenting were performed by standard methods.
The decision for detailed treatment was left to the physician’s
discretion. Clinical follow-upwas performed in patients at 1, 6, and
12 months after discharge from the hospital.
Statistical analysis
The Statistical Package for Social Science (SPSS, Chicago, IL, USA)
for Windows, version 18.0 was used for all analysis. Continuous
variables were expressed as mean  standard deviation or median
(interquartile range), and compared with Student’s t test or Mann–
Whitney test. Categorical variables were expressed as percentage and
compared with Chi-square test.
Multivariate survival analysis using Cox proportional hazard
models was performed. Important risk covariates which had
signiﬁcant effects with p < 0.2 in univariate analysis were entered
into Cox proportional hazards model. The following variables were
included in adjustment for in-hospital mortality: age, gender,
atypical symptoms, systolic blood pressure, combined stroke, pre-
procedural thrombolysis inmyocardial infarction (TIMI) grade, left
ventricular ejection fraction (LVEF), creatinine clearance (CrCl),
statin during hospitalization, angiotensin-converting enzyme
inhibitors (ACE inhibitor) or angiotensin receptor blockers (ARB),
high-sensitivity C-reactive protein (hs-CRP), pain, heart rate,
diabetes, troponin T (TnT), cilostazol, nitrates, and lesion type
B2C. Baseline Cox model was established by ‘‘backward stepwise
eliminationmethod’’, and ﬁnally, we added low HDL variable to the
baseline Cox model by ‘‘enter method’’. Results are presented as
adjustedhazard ratios (HRs)with 95% conﬁdence intervals (CIs) and
p-value. All variables were considered statistically signiﬁcant when
p-value was less than 0.05.
Results
Baseline characteristics and angiographic ﬁndings
A total of 9270 AMI patients were included. Median HDL level
was 43.0 mg/dL. Baseline clinical characteristics are listed in
Table 1. In both populations, patients with low HDL were older,
more often female, and had more comorbid diseases and worse
clinical features such as higher Killip class or reduced renal
function.
Angiographic characteristics are presented in Table 2. The
incidence of multivessel disease was higher in patients with low
HDL in both populations. Pre-procedural TIMI ﬂow grade 0 was
signiﬁcantly more frequent in STEMI patients with low HDL,
but drug-eluting stent (DES) implantation rate was lower in
them.Clinical outcomes
In-hospital death and 12-month clinical outcomes are shown
in Table 3. In-hospital death occurred in 172 (2.8%) patients with
STEMI, and 42 (1.3%) patients with NSTEMI. In-hospital death
rate was signiﬁcantly higher in low HDL group than normal HDL
group in STEMI population, while there was no signiﬁcant
difference in NSTEMI population. Pump failure was the major
cause of in-hospital deaths and it was higher in low HDL group
than normal HDL group in STEMI population. Twelve-month
MACE occurred in 470 (5.2%) patients among hospital survivors,
and there was no signiﬁcant difference between two groups in
both populations.
Inmultivariate analysis, lowHDLwas an independent predictor
of in-hospital mortality in STEMI population (HR: 2.380, 95% CI:
1.143–4.956, adjusted p = 0.020), but not in NSTEMI population
(HR: 1.231, 95% CI: 0.649–2.335, adjusted p = 0.525) (Figs. 2 and 3).
It was not an independent predictor of 12-month MACE in both
populations (Figs. 3 and 4). Other independent predictors of in-
hospital death in STEMI population were combined stroke, low
LVEF, low CrCl, rapid heart rate, and TnT.
Subgroup analysis
Very low HDL subgroup showed the highest in-hospital
mortality rate, compared with other subgroups in both popula-
tions (Fig. 5).
Discussion
The major ﬁnding of this study was that low HDL was an
independent predictor of in-hospital mortality in STEMI patients,
but not in NSTEMI patients, although very low HDL was associated
with higher risk. In hospital survivors, there was no signiﬁcant
difference in 12-month MACE rates between the two groups of
both populations.
Previous studies have shown controversies about the impact of
low HDL on clinical outcomes in non-ST-segment-elevation acute
coronary syndrome (NSTE-ACS) patients [4–6], whereas there is a
lack of data in STEMI patients. In agreement with our results,
Acharjee et al. [6] reported that very lowHDL, but not lowHDL,was
associated with higher in-hospital mortality rate in NSTEMI
patients. In contrast to our results, Wolfram et al. [4] reported
that low HDL was an independent predictor of 12-month MACE in
NSTE-ACS patients. Discrepancy in results between our study and
the study byWolfram et al. [4]might be attributed to differences in
study populations, in diagnostic criteria for low HDL, and in racial
characteristics between studies.
Importantly, this study found that in the STEMI population, low
HDL was signiﬁcantly associated with higher in-hospital mortality
rate. These ﬁndings might support and add some new evidence to
the previous studies, and suggest that the hazardous effect of low
HDL appeared to be prominent in STEMI patients rather than in
NSTEMI patients.
There are possible mechanisms to explain our results. One
is difference in plaque compositions between STEMI and
NSTEMI [11,12]. Contrary to NSTEMI, plaque in STEMI is mainly
composed of intra-plaque hemorrhage from neovascularization,
a major cause of plaque vulnerability [13,14]. Recently, HDL has
been reported to be an independent predictor of plaque rupture
and to inhibit neo-vascularization [15,16]. In our study,
pre-procedural TIMI ﬂow grade 0 was more frequent in low
HDL group of STEMI population than normal HDL group
(p = 0.035), but not in NSTEMI (p = 0.425). These ﬁndings might
support stronger impact of low HDL on clinical outcome of
STEMI than NSTEMI.
Table 1
Baseline characteristics in STEMI and in NSTEMI.
Variables STEMI (N=6110) NSTEMI (N=3160)
Low HDL (N=2667) Normal HDL (N=3443) p Low HDL (N=1514) Normal HDL (N=1646) p
Age (years)a 64.9 (54.2,73.1) 61.3 (51.6,70.5) <0.001 65.9 (55.7,73.3) 62.9 (52.9,71.5) <0.001
Men 1710 (64.1) 2890 (84.0) <0.001 886 (58.5) 1297 (79.0) <0.001
Prior history
DM 781 (29.6) 724 (21.3) <0.001 553 (37.0) 425 (25.9) <0.001
Hypertension 1312 (49.8) 1423 (41.8) <0.001 853 (56.8) 812 (49.7) <0.001
Dyslipidemia 231 (10.0) 276 (9.1) 0.259 195 (14.9) 209 (14.2) 0.605
Previous CAD 312 (11.7) 378 (11.0) 0.381 314 (20.8) 293 (17.8) 0.036
Combined stroke 179 (6.7) 158 (4.6) <0.001 132 (8.7) 110 (6.7) 0.032
Smoking history 1524 (57.6) 2345 (68.5) <0.001 746 (49.4) 1006 (61.8) <0.001
Family history 179 (7.5) 242 (7.8) 0.655 98 (7.1) 124 (8.2) 0.252
Chest pain 2342 (89.5) 3078 (90.4) 0.235 1240 (83.1) 1340 (82.4) 0.606
Atypical symptom 334 (12.6) 338 (9.9) 0.001 282 (18.7) 310 (18.9) 0.911
Symptom to door time (min) 220 (106, 589) 211 (107, 543) 0.291 430 (175, 1601) 2070 (840, 5273) 0.066
Door to balloon time (min) 115 (70, 147) 123 (74, 1529) 0.008 405 (157, 1354) 1698 (637, 4794) 0.027
Prodromal angina 1097 (41.3) 1219 (35.7) <0.001 800 (53.0) 823 (50.2) 0.116
WC (cm) 93.878.83 90.456.34 0.092 89.946.87 90.448.55 0.807
BMI (kg/m2) 24.3 (22.2, 26.7) 24.0 (22.0, 26.2) <0.001 24.2 (22.4, 26.4) 24.2 (22.2, 26.6) 0.742
SBP (mmHg) 123.829.81 128.531.56 <0.001 132.334.95 134.327.11 0.081
LVEF (%) 50.814.28 50.915.51 0.935 53.412.31 55.314.92 <0.001
Killip class> II 326 (12.6) 336 (10.0) 0.002 148 (10.0) 125 (7.7) 0.028
Anterior wall MI 1267 (48.3) 1878 (55.6) <0.001 523 (36.9) 574 (36.6) 0.869
Glucose (mg/dL) 179.083.48 167.369.66 <0.001 164.782.88 155.274.82 0.001
CrCl (mL/min) 67.3 (48.2, 89.5) 73.2 (55.9, 93.1) <0.001 65.5 (46.5, 86.3) 74.0 (56.0, 93.3) <0.001
TG (mg/dL) 136.6116.14 115.6107.76 <0.001 145.191.85 124.196.40 <0.001
LDL (mg/dL) 113.340.29 121.245.57 <0.001 116.643.00 121.942.27 <0.001
HDL (mg/dL) 35.66.62 53.132.03 <0.001 35.76.85 53.023.81 <0.001
CK-MB 125.6 (38.3, 267.0) 144.9 (47.9, 298.7) <0.001 32.0 (10.2, 90.0) 38.2 (12.9, 109.1) <0.001
hs-CRP (mg/L) 5.2 (1.7, 21.9) 4.0 (1.3, 16.5) <0.001 5.5 (1.8, 22.4) 3.8 (1.2, 15.1) <0.001
NT-proBNP (pg/mL) 444.0 (93.0, 1817.5) 305.0 (69.0, 1365.0) <0.001 677.0 (177.0, 2186.0) 436.0 (146.0, 1244.0) <0.001
Troponin T (ng/mL)a 3.5 (0.8, 8.8) 3.3 (0.8, 8.6) 0.781 1.0 (0.3, 3.2) 0.8 (0.3, 2.4) 0.062
In-hospital medication
Gp2b3a inhibitor 427 (16.0) 498 (14.5) 0.091 110 (7.3) 125 (7.6) 0.719
ACEI/ARB 2123 (79.9) 2875 (83.7) <0.001 1209 (80.1) 1359 (82.9) 0.047
Beta-blocker 1922 (72.3) 2603 (75.8) 0.002 1168 (77.4) 1237 (75.4) 0.192
Aspirin 2646 (99.5) 3415 (99.4) 0.580 1500 (99.4) 1632 (99.5) 0.678
Clopidogrel 2635 (99.1) 3392 (98.8) 0.178 1491 (98.8) 1621 (98.8) 0.929
Cilostazol 900 (33.9) 1337 (38.9) <0.001 470 (31.1) 586 (35.7) 0.006
Statin 2138 (80.4) 2735 (79.6) 0.444 1179 (78.1) 1296 (79.0) 0.542
Statin prior to onset of AMI 138 (5.2) 172 (5.0) 0.016 129 (8.5) 146 (8.9) 0.026
Complications 462 (17.4) 447 (13.0) <0.001 109 (7.2) 93 (5.7) 0.076
Data are presented as the n (%) of patients ormean SD. STEMI, ST-segment-elevationmyocardial infarction; NSTEMI, non-ST-segment-elevationmyocardial infarction; HDL,
high-density lipoprotein cholesterol; DM, diabetes mellitus; CAD, coronary artery disease; WC, waist circumference; BMI, body mass index; SBP, systolic blood pressure; LVEF,
left ventricular ejection fraction; MI, myocardial infarction; CrCl, creatinine clearance; TG, triglycerides; LDL, low-density lipoprotein cholesterol; CK-MB, creatine kinase MB;
hsCRP, high-sensitivity C-reactive protein; NTproBNP, N-terminal pro-B type natriuretic peptide; Gp2b3a inhibitor, glycoprotein 2b3a inhibitor; ACEI, angiotensin-converting
enzyme inhibitors; ARB, angiotensin receptor blockers; AMI, acute myocardial infarction.
a Values are expressed as the median (interquartile range).
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resistance and metabolic syndrome [17,18]. Previous studies
reported the relation of abdominal obesity to HDL levels and
function [19,20]. In our study, very low HDL subgroup in STEMI
population had the highest mean waist circumference level
(97.3 cm vs. 93.3 cm vs. 90.4 cm), as well as the highest in-
hospital mortality rate among the subgroups. These results might
suggest that the degree of HDL level might be related to the
severity of abdominal obesity and to clinical outcome in AMI
patients.
There are some aspects of concern in this study. Suboptimal
treatments were more often given to STEMI patients with low HDL
than those with normal HDL. ACEI and DES were less used, and
statin treatment which is effective for plaque regression [21] was
insufﬁcient for them. These ﬁndings might be attributed to their
worse clinical features and poor recognition for plaque-stabilizing
therapy by physicians in a real-world clinic. Therefore, this study
suggests that more aggressive treatment including statin and
additional plaque stabilizing therapy such as apolipoprotein A-I
[22], needs to be considered in STEMI patients with low HDL.Statin administration before onset of AMI or before procedure is
reported to be effective to prevent microcirculation impairment in
AMI patients [23–25]. However, in our study, it did not affect in-
hospital mortality in them (adjusted p > 0.05). Differences in
results might be attributed to small numbers of treated patients
and the possibility of selection bias as well as to differences in
primary endpoints, which was in-hospital death in our study but
no-reﬂow or infarct size in other studies. Moreover, data related to
statin treatment during hospitalization, which was beneﬁcial for
clinical outcomes of AMI patients [26], was not presented in those
studies, contrary to our study. Therefore, further study is needed
regarding this issue.
Recent studies [27,28] have suggested that sex differencemight
affect patients’ prognosis in AMI patients; however, our study
found that sex difference itself was not an independent predictor of
in-hospital mortality or 12-month MACE or TVR in this population
(adjusted p > 0.05). Additionally, in our study, prolonged symp-
tom-to-door time or door-to-balloon time was not associated with
12-month mortality (adjusted p > 0.05) in STEMI patients. This
result was in accordance with a recent study which reported that
Table 2
Coronary angiographic ﬁndings in STEMI and in NSTEMI.
Variables STEMI NSTEMI
Low HDL (N=2667) Normal HDL (N=3443) p Low HDL (N=1514) Normal HDL (N=1646) p
Culprit coronary artery
LAD 1251 (46.9) 1878 (54.5) <0.001 602 (39.8) 663 (40.3) 0.767
LCX 243 (9.1) 335 (9.7) 0.413 442 (29.2) 495 (30.1) 0.589
LM 34 (1.3) 42 (1.2) 0.350 33 (2.2) 45 (2.7) 0.319
RCA 1135 (42.6) 1180 (34.3) <0.001 431 (28.5) 439 (26.7) 0.259
Involved vessel number
One 1140 (43.0) 1723 (50.4) <0.001 496 (33.0) 659 (40.2) <0.001
Two 845 (31.8) 1029 (30.1) 0.143 510 (33.9) 552 (33.7) 0.382
Three 614 (23.1) 600 (17.5) <0.001 445 (29.6) 378 (23.0) <0.001
Left main 55 (2.1) 68 (2.0) 0.818 53 (3.5) 51 (3.1) 0.517
ACC/AHA lesion type
A 95 (3.8) 124 (3.9) 0.965 60 (4.3) 64 (4.2) 0.877
B1 468 (18.9) 582 (18.1) 0.448 254 (18.4) 288 (19.0) 0.663
B2 651 (26.3) 893 (27.8) 0.207 434 (31.4) 475 (31.3) 0.978
C 1266 (51.0) 1619 (50.3) 0.581 635 (45.9) 689 (45.4) 0.801
Pre-PCI TIMI ﬂow grade
0 1387 (54.4) 1708 (51.6) 0.035 408 (28.7) 423 (27.4) 0.425
I 254 (10.0) 361 (10.9) 0.240 190 (13.4) 180 (11.7) 0.158
II 365 (14.3) 515 (15.6) 0.184 276 (19.4) 301 (19.5) 0.961
III 544 (21.3) 725 (21.9) 0.595 546 (38.5) 639 (41.4) 0.100
Post-PCI TIMI ﬂow grade
0 28 (1.1) 18 (0.5) 0.018 9 (0.6) 4 (0.3) 0.118
I 6 (0.2) 15 (0.5) 0.165 5 (0.4) 2 (0.1) 0.207
II 106 (4.2) 113 (3.4) 0.141 25 (1.8) 36 (2.3) 0.293
III 2400 (94.5) 3144 (95.6) 0.060 1370 (97.2) 1507 (97.3) 0.925
Multi-vessel disease 1514 (57.0) 1697 (49.6) <0.001 1008 (67.0) 981 (59.8) <0.001
Lesion type B2/C 1917 (77.3) 2512 (78.1) 0.493 1069 (77.3) 1164 (76.8) 0.742
DES 2262 (89.5) 3006 (91.8) 0.003 1329 (92.9) 1431 (91.8) 0.263
Stent size 25.36.45 24.96.13 0.025 25.06.90 24.66.60 0.063
Stent diameter 3.180.44 3.20 0.44 0.074 3.080.42 3.120.43 0.011
Stent number 1.460.81 1.430.76 0.175 1.700.96 1.610.91 0.013
Data are presented as the n (%) of patients or mean SD. STEMI, ST-segment-elevationmyocardial infarction; NSTEMI, non-ST-segment-elevationmyocardial infarction; HDL,
high-density lipoprotein cholesterol; LAD, left anterior descending artery; LCX, left circumﬂex artery; RCA, right coronary artery; LM, left main coronary artery; ACC/AHA,
American College of Cardiology/American Heart Association; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction; DES, drug-eluting stent.
Table 3
Clinical outcomes according to low level HDL.
Variables STEMI (N=6110) NSTEMI (N=3160)
Low HDL (N=2667) Normal HDL (N=3443) Log rank p Low HDL (N=1514) Normal HDL (N=1646) Log rank p
In-hospital death 124 (4.6) 48 (1.4) <0.001 27 (1.8) 15 (0.9) 0.120
Pump failure 69 (2.6) 24 (0.7) 11 (0.7) 8 (0.5)
Mechanical Cx 8 (0.3) 2 (0.1) 3 (0.2) 1 (0.06)
Arrhythmia 8 (0.3) 6 (0.2) 3 (0.2) 1 (0.06)
Other cardiac cause 9 (0.3) 8 (0.2) 2 (0.1) 2 (0.1)
Multi-organ failure 9 (0.3) 7 (0.2) 4 (0.3) 2 (0.1)
Non-cardiac death 21 (0.8) 1 (0.03) 4 (0.3) 1 (0.06)
Variables STEMI (N=6110) NSTEMI (N=3160)
Low HDL (N=2543) Normal HDL (N=3395) Log rank p Low HDL (N=1487) Normal HDL (N=1631) Log rank p
12-month outcome in hospital survivors
Cardiac death 45 (1.8) 47 (1.4) 0.241 22 (1.5) 18 (1.1) 0.364
Non-fatal MI 20 (0.8) 14 (0.4) 0.065 15 (1.0) 13 (0.8) 0.539
TVR 78 (3.1) 100 (2.9) 0.807 49 (3.3) 56 (3.4) 0.859
MACE 141 (5.5) 159 (4.7) 0.145 84 (5.6) 86 (5.3) 0.651
All comparisons were made by the Chi-square test and Log rank p value was calculated by Kaplan–Meier analysis. STEMI, ST-segment-elevation myocardial infarction;
NSTEMI, non-ST-segment-elevation myocardial infarction; HDL, high-density lipoprotein cholesterol; Mechanical Cx, mechanical complication; MI, myocardial
infarction; TVR, target vessel revascularization; MACE, major adverse cardiac event(s). Major adverse cardiac events (MACE) included cardiac deaths, recurrent
myocardial infarction, and target vessel revascularization.
M.S. Ji et al. / Journal of Cardiology 65 (2015) 63–70 67prolonged symptom-to-balloon time was not associated with
long-term mortality [29].
The major strength of this study is the large sample size and
study design analyzing impact of low HDL on clinical outcome,
which is different from previous studies. This is the ﬁrst study to
our knowledge to show the impact of low HDL on clinical outcome
and its timing in STEMI population.Our study had some limitations. First, it was a retrospective
study, and therewere possibilities of selection bias ormissing data.
Second, detailed analysis according to the previous HDL level
before admission was not performed. Although there were
concerns that lipid levels after admission were signiﬁcantly
affected by patients’ status, one study demonstrated that HDL
level obtained within the ﬁrst 24–48 h of admission reﬂects the
[(Fig._2)TD$FIG]
Fig. 2. In-hospital mortality rate. Low HDL was associated with signiﬁcantly higher risk of in-hospital mortality in STEMI patients (A), but not in NSTEMI patients (B). HDL,
high-density lipoprotein; STEMI, ST-segment-elevation myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction.
[(Fig._3)TD$FIG]
Fig. 3. Forest plot. Low HDL was an independent predictor of in-hospital mortality in STEMI, but not in NSTEMI. HR, hazard ratio; CI, conﬁdence interval; HDL, high-density
lipoprotein; STEMI, ST-segment-elevation myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; MI, myocardial infarction; TVR, target vessel
revascularization; MACE, major adverse cardiac events.
M.S. Ji et al. / Journal of Cardiology 65 (2015) 63–7068baseline status [30]. Based on the results of these previous studies,
the present study might overcome this limitation. Finally,
lipoprotein proﬁles were measured neither in the course of
hospitalization nor at 4–6 weeks after onset of AMI. Thus, more
controlled studies are needed in future.Nevertheless, the ﬁndings of this study might have clinical
implications. First, low HDL might be a potential biomarker
for plaque rupture in STEMI patients. Second, early stage of
AMI might be more appropriate time for HDL-related treatment
to reduce in-hospitalmortality in STEMI patients. Finally, attention
[(Fig._5)TD$FIG]
Fig. 5. In-hospital mortality rate according to HDL level. Very low HDL subgroup showed higher in-hospital mortality rate compared with other subgroups. (A) STEMI and (B)
NSTEMI. HDL, high-density lipoprotein; STEMI, ST-segment-elevation myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction.
[(Fig._4)TD$FIG]
Fig. 4. Twelve-month MACE rates in hospital survivors. (A) STEMI (B) NSTEMI. MACE, major adverse cardiac events; HDL, high-density lipoprotein; STEMI, ST-segment-
elevation myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction.
M.S. Ji et al. / Journal of Cardiology 65 (2015) 63–70 69must be paid to reduce abdominal obesity in those who are at
risk.
In conclusion, this study showed that low HDL was associated
with signiﬁcantly higher risk of in-hospital mortality in STEMI
patients, but not in NSTEMI patients. Thus, early detection
for low HDL is important in STEMI patients, and more
aggressive treatment including plaque stabilizing therapy
during early stage should be considered in STEMI patients with
low HDL.Conﬂict of interest
There are no potential conﬂicts to declare.
Acknowledgments
This study was performed with the support of the Korean
Circulation Society in commemoration of its 50th Anniversary, the
Korean Health Technology R&D Project (HI13C1527) and Ministry
M.S. Ji et al. / Journal of Cardiology 65 (2015) 63–7070of Health &Welfare, Republic of Korea. The authors thank all of the
clinical investigators who contributed time and effort to this study.
Korea Acute Myocardial Infarction (KAMIR) investigators:
Myung Ho Jeong MD, Young Keun Ahn MD, Shung Chull Chae
MD, Jong Hyun Kim MD, Seung Ho Hur MD, Young Jo Kim MD, In
Whan SeongMD, DongHoon ChoiMD, Jei Keon ChaeMD, Taek Jong
HongMD, Jae Young RhewMD,Doo Il KimMD, InHoChaeMD, Jung
Han Yoon MD, Bon Kwon Koo MD, Byung Ok Kim MD, Myoung
Yong Lee MD, Kee Sik Kim MD, Jin Yong Hwang MD, Myeong Chan
ChoMD, Seok Kyu OhMD, Nae Hee Lee MD, Kyoung Tae Jeong MD,
Seung JeaTahk MD, Jang Ho Bae MD, Seung-Woon Rha MD, Keum
Soo Park MD, Chong Jin KimMD, Kyoo Rok Han MD, Tae Hoon Ahn
MD, Moo Hyun Kim MD, Ki Bae Seung MD, Wook Sung Chung MD,
Ju Young Yang MD, Chong Yun Rhim MD, Hyeon Cheol Gwon MD,
SeongWook Park MD, Young Youp Koh MD, Seung Jae Joo MD, Soo
Joong Kim MD, Dong Kyu Jin MD, Jin Man Cho MD, Yang Soo Jang
MD, Jeong Gwan Cho, MD, and Seung Jung Park MD.
References
[1] Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-
density lipoprotein cholesterol levels. Heart 2008;94:706–14.
[2] Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ,
Bittner V, Fruchart JC, Treating to New Targets Investigators. HDL cholesterol,
very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med
2007;357:1301–10.
[3] Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver
MF, Waters D, Zeiher A. High-density lipoprotein, but not low-density
lipoprotein cholesterol levels inﬂuence short-term prognosis after acute
coronary syndrome: results from the MIRACL trial. Eur Heart J 2005;26:
890–6.
[4] Wolfram RM, Brewer HB, Xue Z, Satler LF, Pichard AD, Kent KM, Waksman R.
Impact of low high-density lipoproteins on in-hospital events and one-year
clinical outcomes in patients with non-ST-elevation myocardial infarction
acute coronary syndrome treated with drug-eluting stent implantation. Am
J Cardiol 2006;98:711–7.
[5] Roe MT, Ou FS, Alexander KP, Newby LK, Foody JM, Gibler WB, Boden WE,
Ohman EM, Smith Jr SC, Peterson ED. Patterns and prognostic implications of
low high-density lipoprotein levels in patients with non-ST-segment elevation
acute coronary syndromes. Eur Heart J 2008;29:2480–8.
[6] Acharjee S, Roe MT, Amsterdam EA, Holmes DN, Boden WE. Relation of
admission high-density lipoprotein cholesterol level and in-hospital mortality
inpatientswithacutenon-ST segmentelevationmyocardial infarction (fromthe
National Cardiovascular Data Registry). Am J Cardiol 2013;112:1057–62.
[7] Fabregat-Andres O, Ferrando-Beltran M, Lucas-Inarejos E, Estornell-Erill J,
Facila L, Ridocci-Soriano F. High-density lipoproteins and myocardial necrosis
in patients with acute myocardial infarction and ST segment elevation. Rev
Clin Esp 2013;213:75–80.
[8] Abbott JD, Ahmed HN, Vlachos HA, Selzer F, Williams DO. Comparison of
outcome in patients with ST-elevation versus non-ST-elevation acute myocar-
dial infarction treated with percutaneous coronary intervention (from the
National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol
2007;100:190–5.
[9] Sim DS, Kim JH, Jeong MH. Differences in clinical outcomes between patients
with ST-elevation versus non-ST-elevation acute myocardial infarction in
Korea. Korean Circ J 2009;39:297–303.
[10] Cutlip DE,Windecker S,Mehran R, BoamA, CohenDJ, van Es GA, Steg PG,Morel
MA,Mauri L, Vranckx P,McFadden E, Lansky A, HamonM, KrucoffMW, Serruys
PW, et al. Clinical end points in coronary stent trials: a case for standardized
deﬁnitions. Circulation 2007;115:2344–51.
[11] Quadros AS, Cambruzzi E, Sebben J, David RB, Abelin A, Welter D, Sarmento-
Leite R, Mehta RH, Gottschall CA, Lopes RD. Red versus white thrombi
in patients with ST-elevation myocardial infarction undergoing primarypercutaneous coronary intervention: clinical and angiographic outcomes.
Am Heart J 2012;164:553–60.
[12] Hong YJ, Jeong MH, Choi YH, Ma EH, Ko JS, Lee MG, Park KH, Sim DS, Yoon NS,
Youn HJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, et al. Differences in
intravascular ultrasound ﬁndings in culprit lesions in infarct-related arteries
between ST segment elevation myocardial infarction and non-ST segment
elevation myocardial infarction. J Cardiol 2010;56:15–22.
[13] Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP,
Narula J. Atherosclerotic plaque progression and vulnerability to rupture:
angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb
Vasc Biol 2005;25:2054–61.
[14] Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and
hypoxia in atherosclerosis. J Pathol 2009;218:7–29.
[15] Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC. High-density
lipoprotein function recent advances. J Am Coll Cardiol 2005;46:1792–8.
[16] Kato M, Dote K, Naganuma T, Sasaki S, Ueda K, Okita M, Watanabe Y, Kajikawa
M, Yokoyama H, Higashi A. Clinical predictors of culprit plaque rupture
assessed on intravascular ultrasound in acute coronary syndrome. Circ J
2010;74:1936–42.
[17] Greenberg AS, ObinMS. Obesity and the role of adipose tissue in inﬂammation
and metabolism. Am J Clin Nutr 2006;83:461S–5S.
[18] Goyal SN, Bharti S, Krishnamurthy B, Agrawal Y, Ojha SK, Arya DS. Impact of
metabolic syndrome on re-stenosis development: role of drug-eluting stents.
Diab Vasc Dis Res 2012;9:177–88.
[19] Rashid S, Genest J. Effect of obesity on high-density lipoprotein metabolism.
Obesity (Silver Spring) 2007;15:2875–88.
[20] Persegol L, Verges B, Gambert P, Duvillard L. Inability of HDL from abdominally
obese subjects to counteract the inhibitory effect of oxidized LDL on vasor-
elaxation. J Lipid Res 2007;48:1396–401.
[21] Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J,
Magorien RD, O’Shaughnessy C, Ganz P, Reversal of Atherosclerosis with
Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL,
cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med
2005;352:29–38.
[22] Reimers GJ, Jackson CL, Rickards J, Chan PY, Cohn JS, Rye KA, Barter PJ, Rodgers
KJ. Inhibition of rupture of established atherosclerotic plaques by treatment
with apolipoprotein A-I. Cardiovasc Res 2011;91:37–44.
[23] Iwakura K, Ito H, Kawano S, Okamura A, Kurotobi T, Date M, Inoue K, Fujii K.
Chronic pre-treatment of statins is associated with the reduction of the no-
reﬂow phenomenon in the patients with reperfused acute myocardial infarc-
tion. Eur Heart J 2006;27:534–9.
[24] Ishii H, Ichimiya S, Kanashiro M, Aoyama T, Ogawa Y, Murakami R, Amano T,
Naruse K, Matsubara T, Murohara T. Effects of receipt of chronic statin therapy
before the onset of acute myocardial infarction: a retrospective study in
patients undergoing primary percutaneous coronary intervention. Clin Ther
2006;28:1812–9.
[25] Kiyokuni M, Kosuge M, Ebina T, Hibi K, Tsukahara K, Okuda J, Iwahashi N,
Maejima N, Kusama I, Komura N, Nakayama N, Umemura S, Kimura K.
Effects of pretreatment with statins on infarct size in patients with acute
myocardial infarction who receive ﬁbrinolytic therapy. Circ J 2009;73:
330–5.
[26] de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL,
Pedersen TR, Gardner LH,Mukherjee R, Ramsey KE, Palmisano J, BilheimerDW,
Pfeffer MA, Califf RM, et al. Early intensive vs a delayed conservative simva-
statin strategy in patients with acute coronary syndromes: phase Z of the A to
Z trial. JAMA 2004;292:1307–16.
[27] Jneid H, FonarowGC, Cannon CP, Hernandez AF, Palacios IF,Maree AO,Wells Q,
Bozkurt B, Labresh KA, Liang L, Hong Y, Newby LK, Fletcher G, Peterson E,
Wexler L, et al. Sex differences in medical care and early death after acute
myocardial infarction. Circulation 2008;118:2803–10.
[28] Lawesson SS, Alfredsson J, Fredrikson M, Swahn E. A gender perspective on
short- and long termmortality in ST-elevationmyocardial infarction – a report
from the SWEDEHEART register. Int J Cardiol 2013;168:1041–7.
[29] Cho YW, Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim DI, Lee SH, Cho YK, Kim
DS. Relationship between symptom-onset-to-balloon time and long-term
mortality in patients with acute myocardial infarction treated with drug-
eluting stents. J Cardiol 2011;58:143–50.
[30] Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syn-
dromes. J Am Coll Cardiol 2008;51:1440–5.
